Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PRECISION BIOSCIENCES INCDTIL · Entity 6284 | Chief Financial Officer | June 01, 2026 | June 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PRECISION BIOSCIENCES INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 193,688 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 193,688 · Balance 193,688 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Award vests in three substantially equal annual installments beginning on February 19, 2027, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2022 Filed Nov 4, 2022 20:14 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 324,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055788 · doc4.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 324,500 Underlying: Common Stock · 324,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Award represents a retention grant, which vests in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. F2 · derivative.expiration_date: Award represents a retention grant, which vests in three substantially equal annual installments beginning on November 2, 2023, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| September 23, 2022 Filed Sep 26, 2022 20:10 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 8,200 | $1.23 | $10,086.00 |
DisclosureSEC source: 0001209191-22-051240 · doc4.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,938 Read SEC document |
| September 22, 2022 Filed Sep 26, 2022 20:10 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 37,037 | $1.34 | $49,629.58 |
DisclosureSEC source: 0001209191-22-051240 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,738 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.34 to $1.35. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 12:59 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 33,784 | $1.50 | $50,676.00 |
DisclosureSEC source: 0001209191-22-039100 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,701 Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 13,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035405 · doc4.xml · derivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,270 Underlying: Common Stock · 13,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F4 · derivative.exercise_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F4 · derivative.expiration_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in three substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionRestricted Stock Units · Derivative | 34,090 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035405 · doc4.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,091 Underlying: Common Stock · 34,090 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in two substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates F3 · derivative.expiration_date: On June 7, 2021 the Reporting person was granted RSUs, which vest in two substantially equal annual installments beginning on June 7, 2022, subject to the Reporting Person's continued service to the Company through the applicable vesting dates Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 13,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-035405 · doc4.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2 · price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | Exercise / conversionCommon Stock | 34,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-035405 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the partial vesting and settlement of Restricted Stock Units ("RSUs") on June 7, 2022. F2 · price: Each RSU represents a contingent right to receive one share of the Company's Common Stock. Read SEC document |
| March 17, 2022 Filed Mar 21, 2022 22:22 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | PurchaseCommon Stock | 16,677 | $3.08 | $51,365.16 |
DisclosureSEC source: 0001209191-22-020337 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,189 F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $3.05 to $3.09. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 153,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016614 · doc4.xml · derivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,185 Underlying: Common Stock · 153,185 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F3 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 21:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 243,274 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001209191-22-016614 · doc4.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,274 Underlying: Common Stock · 243,274 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on March 3, 2023 and thereafter in twelve substantially equal installments at the end of each three-month period over the 36 months following such date, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| February 28, 2022 Filed Mar 7, 2022 21:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 2,714 | $3.61 | $9,797.54 |
DisclosureSEC source: 0001209191-22-016614 · doc4.xml · nonDerivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,512 Read SEC document |
| August 31, 2021 Filed Mar 7, 2022 21:08 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantCommon Stock | 998 | $10.68 | $10,658.64 |
DisclosureSEC source: 0001209191-22-016614 · doc4.xml · nonDerivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,798 Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 40,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 4 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,908 Underlying: Common Stock · 40,908 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F5 · derivative.exercise_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. F5 · derivative.expiration_date: The RSUs shall vest in three substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 70,295 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 3 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,295 Underlying: Common Stock · 70,295 shares Expires 2031-06-06 F4 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantRestricted Stock Units · Derivative | 68,181 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 2 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,181 Underlying: Common Stock · 68,181 shares Expires not disclosed F2 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which each represent a contingent right to receive one share of the Company's Common Stock. F3 · derivative.exercise_date: The RSUs shall vest in two substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. F3 · derivative.expiration_date: The RSUs shall vest in two substantially equal annual installments on the anniversary of the grant date of such RSUs, subject to the Reporting Person's continued service to the Company through the applicable vesting dates. Any unvested RSUs shall vest upon The Reporting Person's termination without cause or resignation for good reason prior to June 7, 2022. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 22:30 UTC | PRECISION BIOSCIENCES INC DTIL · Entity 6284 | GrantEmployee Stock Option (Right to Buy) · Derivative | 117,159 | $0.00 Strike: $11.34 | $0.00 |
DisclosureSEC source: 0001209191-21-039269 · doc4.xml · derivative · entry 1 Kelly John Alexander · CIK 0001590030 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,159 Underlying: Common Stock · 117,159 shares Expires 2031-06-06 F1 · derivative.exercise_date: The option vests as to 25% of the underlying shares on June 7, 2022 and thereafter in twelve equal installments at the end of each three-month period over the 36 months following such date. Any unvested options shall vest and become exercisable upon the Reporting Person's termination without cause or resignation due to good reason prior to June 7, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.